Industry

Pharma & HCP

How patients and healthcare professionals decide: starting, switching and stopping treatments, what cost and coverage do to those decisions, and what doctors weigh that patients never see.

31 insights·11 studies·RSS feed

What do patients and prescribers actually do when the price, the risk or the evidence changes?

  1. #

    48.5%

    48.5% would stop the blood pressure pill once its copay rose from $15 to $60 a month, on top of no felt benefit and afternoon tiredness, up from 14.0% with the tiredness alone and 1.5% with no felt benefit alone. — Patient adherence breaks at the copay: 48.5% would stop a daily blood pressure pill when it jumps from $15 to $60 a month

    base 200

  2. #

    35%

    35.0% would stay on an antidepressant that is helping at $150 a month, against 82.2% at $50 and 97.0% at $10; no clone rates itself more likely to stay on at a higher price. — Antidepressant cost: only 35.0% of US adults prescribed one for depression would stay on it at $150 a month, against 82.2% at $50

    base 197

  3. #

    82%

    82% of US men are not open to getting a hair transplant, and none say they are very open — 82% of US men would not get a hair transplant, and 98% of those who see their hair thinning rule one out

    base 200

  4. #

    89%

    89% give strong praise to Diet-and-Exercise Jordan, against 1% for Medication Jordan, who lost the same 60 pounds (separate samples) — 89% strongly praise weight lost through diet and exercise, against 1% when the same weight is lost on medication

    base 200

  5. #

    65.2%

    65.2% rate a 20-minute meeting with a medical science liaison at least moderately useful to their practice, against 17.7% for a 20-minute meeting with a sales representative about the same kind of medicine — Medical science liaisons: 60.1% of US physicians and other prescribers want real-world and subgroup evidence for patients like theirs, and 65.2% rate a liaison meeting useful against 17.7% for a sales rep

    base 198

Which questions does Brox answer in pharma & hcp?

What has Brox published on pharma & hcp?Newest first

What do people ask about pharma & hcp?

Why do patients stop taking a daily medicine after the first few months, and what would keep them on it?
48.5% of US adults who take a daily prescription medicine (n=200, November 2026) would stop a new blood pressure pill once its copay rose from $15 to $60 a month on top of no felt benefit and afternoon tiredness, against 14.0% before the copay rise and 1.5% with no side effect at all.Read the insight
Why do US adults with depression stop an antidepressant, and what would have kept them on it?
Cost and side effects: 82.2% of US adults prescribed an antidepressant for depression would stay on one that helps at $50 a month but 35.0% at $150, and 51.3% say a quick switch when side effects bother them would keep them on it (n=197, November 2026).Read the insight
What do physicians want from a medical science liaison that a sales rep cannot give them?
Real-world and subgroup evidence for patients like their own: 60.1% of US physicians and other prescribers on the Brox HCP panel name it as what they most want from a medical science liaison that a sales rep cannot give, and 65.2% rate a 20-minute liaison meeting at least moderately useful against 17.7% for a rep meeting (n=198, November 2026).Read the insight
How much does a patient's out-of-pocket cost change what a physician is willing to prescribe?
Between $25 and $75 a month: 4.3% of US physicians and other prescribers outside dermatology would pick a $5 generic over the brand-name medicine they prefer when the brand costs the patient $25 a month, 44.3% at $75 and 62.9% at $150 (n=70, November 2026).Read the insight
After stopping a GLP-1, what do past users turn to for keeping the weight off: a diet program, fitness, supplements or nothing?
In November 2026, 67.5% of US past GLP-1 users said they rely most on eating less or eating differently on their own to keep the weight off after stopping (n=166), against 17.5% on exercise, 12.0% on nothing in particular and 2.4% on a structured diet program.Read the insight
Would a physician trust an AI summary of a new drug's trial data over the label or a rep?
Over the rep but not the label: 55.1% of US physicians and other prescribers on the Brox panel would rely on an AI summary of a new medicine's pivotal trial when every number links to the published paper, none would rely on one with no sources, and 66.2% would ignore the sales rep first against 24.2% the AI summary and 0% the FDA label (n=198, November 2026).Read the insight
What makes a physician try a newly launched medicine in its first six months: the trial data, a peer, the rep, or coverage?
Coverage, more than trial data, decides it in practice: 72.9% of US prescribers outside dermatology are likely to prescribe a newly launched medicine with a clear phase 3 benefit in its first months when it is covered without prior authorization, 54.3% when prior authorization is needed and 22.9% when a patient pays $250 a month, even though 55.7% name trial data as their single biggest trigger (n=70, November 2026).Read the insight
What makes a doctor stop seeing pharma reps altogether?
Being asked too often, and their employer: 66.7% of US clinicians on the Brox HCP panel would decline a 10-minute pharma rep visit every two weeks against 39.4% monthly, and 24 of the 36 who no longer see reps name a practice or health system restriction (n=198, November 2026).Read the insight
What makes a dermatologist choose a JAK inhibitor over a biologic, and what makes them avoid it?
88.9% of US dermatologists on the Brox panel would start a healthy 35-year-old with moderate-to-severe eczema who asks for a pill on an oral JAK inhibitor rather than an injectable biologic when both cost the patient $0 a month, falling to 81.7% at a $30 monthly gap, 69.0% at $75 and 46.8% at $150 (n=126, November 2026).Read the insight
What does a physician need to see before switching a stable patient to a newer therapy, and how much better does it have to be?
58.6% of US clinicians on the Brox panel would keep a patient who has been stable for two years on their current therapy even when a newer one gets 15 more patients in 100 to the treatment goal at the same cost and with similar safety, and 32.5% would still keep them at 30 more (n=169, October 2026).Read the insight

Other industries

How should you read these findings?

Where the numbers come from. Every figure on this site is a predicted response from Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The base under each figure is the number of clones behind it.

Where the real data comes from. The long-form video interviews with the real people the clones are built from. A quote is always shown with the interview line it was predicted from.

What you can take away. Insights publish their tabulation as CSV and JSON: question, option, count, percentage and base. Never per-person rows.

Ask this of your own customers: humans@brox.ai